The medicine supplies genetic direction to human cells leading to antibody production to fight COVID-19.

这种药物为人类细胞提供遗传方向，从而使其产生对抗新冠肺炎的抗体。

When activated, they set off a new cycle of antibody production.

当被激活时， 它们会引发新的抗体生产周期。

In these sorts of infections, IgA1 antibody production gets ramped up, leading to IgG anti-glycan formation, and immune complex deposition in the glomerular mesangium, causing inflammation.

在这些感染情况下，IgA1抗体产生增多，导致抗糖基化的抗体IgG形成，免疫复合物便沉积在肾小球系膜，产生炎症反应。